Publicacións en colaboración con investigadores/as de Institute Catalá Oncología (2)

2019

  1. High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance

    Haematologica, Vol. 104, Núm. 11, pp. 2249-2257

2013

  1. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia

    Blood, Vol. 122, Núm. 24, pp. 3951-3959